2871- Iaccarino L, Ghirardello A, CanovaM, ZenM, Bettio S and Nalotto L. (2011): Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. 10:553–8.
2- PanneerDevaraju, ReenaGulati, Paul T, Antony CB and Mithun. (2015): Susceptibility to SLE in South Indian Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes. Volume 64, Issue 1, March 2015, Pages 123–126
3- Somers EC, Marder W and Cagnoli P. (2014): Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol (Hoboken NJ) 66(2):369–378
5- Tsokos GC. (2011): "Systemic lupus erythematosus". N. Engl. J. Med. 365 (22): 2110–21
4- Murphy, G; Isenberg, D (2013): "Effect of gender on clinical presentation in systemic lupus erythematosus.". Rheumatology (Oxford, England) 52 (12): 2108–15
6- Borgia RE and Silverman ED (2015): "Childhood-onset systemic lupus erythematosus: an update.". Current opinion in rheumatology 27 (5): 483–9
7- Bertsias GK, Salmon JE and Boumpas DT. (2010): Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis. 69:1603-1611
8- Jeleniewicz R, Suszek D and Majdan M. (2015): Clinical picture of late-onset systemic lupus erythematosus in a group of Polish patients, Pol Arch Med Wewn. 125(7-8):538-44. Epub 2015 Jun 15
9-George Bertsias, RicardCervera and Dimitrios T Boumpas, (2012): EULAR Textbook on Rheumatic Diseases, Systemic Lupus Erythematosus: Pathogenesis and Clinical Feature. ch 20,479-505
10- Javierre BM, Fernandez AF and Richter J. (2010): Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 20:170-179
11- Somers EC and Richardson BC. (2014): Environmental exposures, epigenetic changes and the risk of lupus. Lupus. 23(6):568–76.
12- Rasmussen NS, Draborg AH, Nielsen CT, Jacobsen S and Houen G. (2015): Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients. Scand J Rheumatol. 44(2):143–9
13- Mak A, Tay S (2014): Environmental factors, toxicants and systemic lupus erythematosus. Int J MolSci 15(9):16043–16056.
14- Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R and Shi H. (2014): Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 40(1):128–39.
15- Kassi E and Moutsatsou P. (2010): Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2010: 317452..
16- Agarwal SK. (2011): Core management principles in rheumatoid arthritis to help guide managed care professionals. Nov-Dec;17(9 Suppl B): S03-8.
17- Scott DL, Wolfe F and Huizinga TW. (2010): "Rheumatoid arthritis". Lancet 376 (9746): 1094–108.
18- Svendsen AJ, Junker P, Houen G, Kyvik KO, Nielsen C, Skytthe A, Holst R. (2016): Incidence of chronic persistent rheumatoid arthritis and the impact of smoking. Arthritis Care Res (Hoboken). Jul 7
19- MacGregor AJ, Snieder H and Rigby AS. (2010): Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43:30-7.
20- Gregersen PK, Silver J and Winchester RJ. (2011): The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30:1205- 13
21- De Almeida DE, Ling S, Pi X, Hartmann-Scruggs AM, Pumpens P and Holoshitz J. (2010): Immune dysregulation by the rheumatoid arthritis shared epitope. J Immunol. 185:1927-34..
22- Klareskog L, Ronnelid J, Lundberg K, Padyukov L and Alfredsson L. (2008): Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 26:651-75.
23- De Rycke L, Peene I and Hoffman IE. (2011): Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis. 63:1587-93.
24- Mahdi H, Fisher BA and Kallberg H. (2009): Specific interaction between genotype, smoking and autoimmunity to citrullinated- alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet. 41:1319- 24
25- Wegner N, Wait R and Sroka A. (2010): Peptidylargininedeiminase from Porphyromonasgingivaliscitrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 62:2662-72..
26- Scher JU, Ubeda C, Pillinger MH, et al. (2010): Characteristic oral and intestinal microbiota in rheumatoid arthritis (RA): a trigger for autoimmunity? Arthritis Rheum. 62:Suppl:1390.
27-Wu M, Schneider DJ, Mayes MD, Assassi S, Arnett FC, Tan FK, Blackburn MR and Agarwal SK. (2012): The role of type 1 interferon in systemic sclerosis. Jun;132(6):1605-14.
28- Vikram B.(2013): A rare case of hidebound disease with dental implications. Dent Res J (Isfahan). 10(4):556–61.
29- Careta MF and Romiti R. (2015): Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 90(1):62–73.
30- Michael. (2012): Sticherling Systemic sclerosis – dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings. Volume 10, Issue 10 October. Pages 705–716
31- Tyndall A and Fistarol S. (2013): The differential diagnosis of systemic sclerosis. CurrOpinRheumatol. 25:692–9.
32- Nguyen C, Berezne A, Baubet T, et al. (2011): Association of Gender with Clinical Expression, Quality of Life, Disability, and Depression and Anxiety in Patients with Systemic Sclerosis. PLoS One. Mar 9. 6(3): e17551.
33- Ungprasert P, Srivali N and Kittanamongkolchai W. (2015): Systemic sclerosis and risk of venous thromboembolism: A systematic review and meta-analysis. Mod Rheumatol. Apr 7. 1-17
34- Arora-Singh RK. (2010): Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J. Autoimmun. 35, 52–57.
35- Broen JC, Coenen M J, and Radstake T R. (2012): Genetics of systemic sclerosis: an update. Curr. Rheumatol. Rep. 14, 11–21.
36- Gorlova O. (2011): Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet. 7, e1002178.
37- Mayes MD. (2014): Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am. J. Hum. Genet. 94, 47–61
38- Ballestar E. (2011): Epigenetic alterations in autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 7, 263–271.
39- Marie I. (2014): Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun. Rev. 13, 151–156.
40-Mammen AL. (2010): Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Jan;1184:134-53.
41- Bendewald MJ, Wetter DA, Li X and Davis MD. (2010): Incidence of dermatomyositis and clinically amyopathicdermatomyositis: apopulation-based study in Olmsted County, Minnesota. Arch Dermatol. Jan. 146(1):26-30.
42- PauliusVenalis and Ingrid E. (2014): Lundberg. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology Journal. 53:397_405.
43- Betteridge ZE, Gunawardena H and McHugh NJ. (2011): Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 13:209.
44- Delaleu N, Nguyen CQ, Peck AB and Jonsson R. (2011): Sjögren's syndrome: studying the disease in mice. Jun 13;13(3):217.
45- Helmick CG, Felson DT and Lawrence RC. (2008): Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. Jan. 58(1):15-25.
46- Sisto M. (2011): A failure of TNFAIP3 negative regulation maintains sustained NF-κB activation in Sjögren‘s syndrome. Histochem. Cell Biol. 135, 615–625.
47- Lessard CJ. (2013): Identification of multiple Sjögren’s syndrome susceptibility loci [abstract OP0020]. Ann. Rheum. Dis. 72 (Suppl. 3), 54.
)
View on SCiNiTO